REMINDER: Our user survey closes on Friday, please submit your responses here.
What the **** is wrong with people on here today! This is aim, the share price will have significant ups and downs. Don’t invest more than you can afford and do your research! If you were looking for a low risk easy ride you should have invested in a fund or Sainsbury’s!
Nothing has changed here, the vaccine news was always going to dent the share price. The reason it’s dropped is those who haven’t done their research are panicking or invested more than they could afford. We have a broad spectrum antiviral drug that effectively turns and any corona virus or any respiratory virus into a mild cold.
Ther are nearly 8billion people in the world, it’s going to take several years before this corona virus is eradicated. It will mutate, new vaccines will be needed. Treatments will be needed!! And lots of them. Immunity from vaccines is still unknown and if it follows reinfection stats may only last 6 months. We have some of the best respiratory doctors and professors in the Uk who have been working on this for 15 years. The science is good and so are the team delivering it. This drug will save many many lives in the coming months. If the p2 trials are anything to go by when the home trial lands I’m expecting the results to be far more significant than any vaccine claim. How many times have you heard RM saying “get the drug into the lungs early”. Well that’s exactly what the home trial is doing. When the results land this is going to the moon and will be snapped up by a large pharma in the blink of an eye. The Sp will dip from here so either average up or sell up and most of all stop moaning! Rant over!
AstraZeneca PLC - AZD1222 vaccine effective against COVID-19 #AZN @AstraZeneca https://www.**********.co.uk/rns/announcement/9ba65ac3-84b0-46a7-911a-b294a04f457c #********** undefined
Interesting that the lower dose is more successful.
Covid-19: Oxford University vaccine shows 70% protection https://www.bbc.co.uk/news/health-55040635
Bad news all round really. How many of these have we pre ordered?
Not sure if this will help things for us. Oh well we still have the rest of the world!
https://twitter.com/profwilko/status/1330613606174646275?s=21
Excellent article thanks for sharing ajithoth. It’s good to see SNG mentioned first here in front of vaccines and other treatments. It feels like Synairgen are upping their PR at the moment which is certainly needed to get the word out. With articles like this it won’t be long before someone important takes notice and gets first in line for our product.
That’s the one :) but with the beeb I’d also take pigeon delivered news as progression.
Sounds like syners are upping their game a bit trying to get the home trial filled here which can only be a good thing. I’m hoping the home trial initial read out should give us EUA.
Yep you heard it here first we got some official beeb coverage earlier on bbc radio Solent. An interview with one of our head researchers talking about the phase 2 and home trials. Listen from 2hours 40 onwards.
https://www.bbc.co.uk/sounds/play/p08x4j5l
Not much today MrBig. Theres a good read at the start of the NIHR thread. The rest is just bickering. The webinar on the 30th is a bit more interesting now as prof Tom Wilkinson is also taking. Oh and pmhj’s medium.com article is worth a look. Other than that usual daily nonsense.
This is even better than I had realised. Just clicked through to register and noticed that Synairgens lead researcher Prof Tom Wilkinson is also taking. I imagine it will be a full walk through if the phase two trials. Schedule as follows:
Agenda:
16.30 - 16.35
Welcome and introduction, Prof Ling-Pei Ho, University of Oxford, R TRC Chair
16:35 - 16.50
Responding to the challenge: the evolving landscape of COVID-19 phase 2 trials in UK, Dr Alex Horsley, University of Manchester, R TRC Deputy Chair
1650 - 17.15
Type I IFN – detection and control of SARS-CoV2, Prof Jan Rehwinkel, University of Oxford
17.15- 17.45
Safety and efficacy of inhaled nebulised interferon beta-1a SARS-CoV-2 infection: a randomised, double-blind, placebo controlled Phase 2 trial, Prof Tom Wilkinson, University of Southampton, SNG001 trial Chief Investigator
17.45 - 18.00
Q&A session moderated by Prof Ling-Pei Ho
Can anyone see this? It’s just been added to the lancet in the last few hours and just showing as a black page on my phone. Maybe one to keep an eye on as they might update it.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30523-3/ppt
Another webinar for your diaries. Co chair of NIH Research Alex Horsely talking about new therapeutic strategies: the story of interferon beta https://twitter.com/manchestercrf/status/1329395923282169856?s=21
I think this is a fair question harchris and one I’ve been battling with too. I think one of the main problems with the current sp is the markets are currently flooded with new traders trying to make a quick profit from COVID stocks. They are short term investers and very twitchy to news. The other risks here are someone beats us to it such as a larger pharma who can get to markers quicker or if COVID is gone by the time we get there. Personally I don’t think either are such a big risk and if we do fail we have COPD to fall back on.
Yep the maths are good here. $3000 per course not per dose. So £2250 x 100,000 x 12 this give us a turn over of 2.7 billion. With 200 mill shares outstanding at around a quid that’s a PSR 0.075!!! Usual caveats of only 70% chance of passing p3 but RM was pretty convinced himself. Then they need to sell them, but again this won’t be a problem if govs stockpile like he said. And this is a very conservative estimate based on limited manufacturing scale up. I really think we are sat on a once in a lifetime share here and the best part about it is in doing so we will be saving lives.